Evidence map›Paper›PMID 27161819›Full record

ArticlePhotochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology2016

Activated T cells exhibit increased uptake of silicon phthalocyanine Pc 4 and increased susceptibility to Pc 4-photodynamic therapy-mediated cell death.

David C Soler, Jennifer Ohtola, Hideaki Sugiyama, Myriam E Rodriguez, Ling Han, Nancy L Oleinick, Minh Lam, Elma D Baron, Kevin D Cooper, Thomas S McCormick

Abstract read
In one paragraph

Article in Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

David C SolerDepartment of Dermatology, Case Western Reserve University, University Hospitals Case Medical Center, Cleveland, OH, USA. tsm4@case.edu.
Jennifer Ohtola
Hideaki Sugiyama
Myriam E Rodriguez
Ling Han
Nancy L Oleinick
Minh Lam
Elma D Baron
Kevin D Cooper
Thomas S McCormick
Case Western Reserve University · USUniversity Hospitals Case Medical Center · USLouis Stokes Cleveland VA Medical Center · USSeirei Hamamatsu General Hospital · JP

Funding

TUMOR METABOLISM PROGRAMP30CA043703 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI MARK R CHANCE · 1987 to 2026
$142.3M
Vitamin D endocrine system and Protection Against Skin TumorlgenesisP30AR039750 · NIAMS · CASE WESTERN RESERVE UNIVERSITY · PI COOPER, KEVIN D · 1988 to 2015
$9.1M
Systems Biology CoreP50AR055508 · NIAMS · CASE WESTERN RESERVE UNIVERSITY · PI DIAZ-INSUA, MIREYA · 2007 to 2011
$6.8M
Psoriatic Regulatory T cell DysfunctionR01AR051498 · NIAMS · CASE WESTERN RESERVE UNIVERSITY · PI COOPER, KEVIN D · 2004 to 2014
$3.5M
NCI NIH HHS P30 CA043703NIAMS NIH HHS P30 AR039750NIAMS NIH HHS P50 AR055508NIAMS NIH HHS R01 AR051498
6 · The paper itself

Abstract

Photodynamic therapy (PDT) is an emerging treatment for malignant and inflammatory dermal disorders. Photoirradiation of the silicon phthalocyanine (Pc) 4 photosensitizer with red light generates singlet oxygen and other reactive oxygen species to induce cell death. We previously reported that Pc 4-PDT elicited cell death in lymphoid-derived (Jurkat) and epithelial-derived (A431) cell lines in vitro, and furthermore that Jurkat cells were more sensitive than A431 cells to treatment. In this study, we examined the effectiveness of Pc 4-PDT on primary human CD3(+) T cells in vitro. Fluorometric analyses of lysed T cells confirmed the dose-dependent uptake of Pc 4 in non-stimulated and stimulated T cells. Flow cytometric analyses measuring annexin V and propidium iodide (PI) demonstrated a dose-dependent increase of T cell apoptosis (6.6-59.9%) at Pc 4 doses ranging from 0-300 nM. Following T cell stimulation through the T cell receptor using a combination of anti-CD3 and anti-CD28 antibodies, activated T cells exhibited increased susceptibility to Pc 4-PDT-induced apoptosis (10.6-81.2%) as determined by Pc 4 fluorescence in each cell, in both non-stimulated and stimulated T cells, Pc 4 uptake increased with Pc 4 dose up to 300 nM as assessed by flow cytometry. The mean fluorescence intensity (MFI) of Pc 4 uptake measured in stimulated T cells was significantly increased over the uptake of resting T cells at each dose of Pc 4 tested (50, 100, 150 and 300 nM, p < 0.001 between 50 and 150 nM, n = 8). Treg uptake was diminished relative to other T cells. Cutaneous T cell lymphoma (CTCL) T cells appeared to take up somewhat more Pc 4 than normal resting T cells at 100 and 150 nm Pc 4. Confocal imaging revealed that Pc 4 localized in cytoplasmic organelles, with approximately half of the Pc 4 co-localized with mitochondria in T cells. Thus, Pc 4-PDT exerts an enhanced apoptotic effect on activated CD3(+) T cells that may be exploited in targeting T cell-mediated skin diseases, such as cutaneous T cell lymphoma (CTCL) or psoriasis.

Indexed as

PhotochemotherapyAnnexin A5ApoptosisAutoantibodiesCD28 AntigensDose-Response Relationship, DrugHumansIndolesLymphoma, T-Cell, CutaneousMitochondriaPhotosensitizing AgentsPlatelet Endothelial Cell Adhesion Molecule-1PropidiumSkin NeoplasmsT-LymphocytesAnnexin A5AutoantibodiesCD28 AntigensIndolesPhotosensitizing Agentsphthalocyanine Pc 4Platelet Endothelial Cell Adhesion Molecule-1Propidium

Identifiers

PMID27161819
PMCPMC4928582
OpenAlexW2343082737

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.